Celltrion develops oral antibody drug with US bio company

The deal with Rani Therapeutics covers joint R&D of RT-111, an antibody drug with autoimmune ingredient ustekinumab

Celltrion develops oral antibody drug with US bio company
Jae-Young Han 1
2023-01-09 13:37:47 jyhan@hankyung.com
Bio & Pharma

South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an oral antibody drug.

RT-111 is an oral drug that uses ustekinumab, an ingredient in autoimmune disease treatment approved for use in the US under the name Stelara and produced by Rani Therapeutics. Rani has the technology to convert intravenous and subcutaneous injection-type proteins and antibody drugs for oral use.

Under the contract, Celltrion will be the exclusive supplier of CT-P43, a biosimilar of the generic bio drug Stelara, required for non-clinical and Phase 1 clinical trials of RT-111, and receive priority negotiation rights for global development and sales. The company recently confirmed the efficiency and safety of CT-P43 in global Phase 3 clinical trials.

In addition to developing RT-111, Celltrion will expand collaboration by applying Rani Therapeutics' technology to other products.

"While developing CT-P43 on our own, we will collaborate on the development of oral treatment using ustekinumab to secure differentiated product competitiveness, and we hope this platform brings innovation and diversity to future pipelines," a Celltrion source said.

Talat Imran, CEO of Rani Therapeutics, said his company looks forward to the results of research and for its partnership with Celltrion to expand.

Write to Jae-Young Han at jyhan@hankyung.com
#Celltrion #Rani Theraputics #US #RT-111 #oral antibody drug #ustekinumab

Celltrion acquires approval to sell Vegzelma in Canada

Celltrion acquires approval to sell Vegzelma in Canada

Celltrion's Vegzelma South Korea's biosimilar heavyweight Celltrion Inc. has obtained permission from the Canadian health ministry to sell anticancer biosimilar Vegzelma, the company said on Thursday.Vegzelma is a biosimilar to Avastin (ingredient name Bevacizumab) used to cure metastatic direc

Celltrion's Remsima receives approval in 100 countries in 10 years

Celltrion's Remsima receives approval in 100 countries in 10 years

Celltrion's Remsima South Korea's most valuable biopharmaceutical company Celltrion Inc. said on Tuesday that its antibody biosimilar Remsima (ingredient: infliximab) has been approved in more than 100 countries ten years after its first approval.Remsima is a TNF-alpha inhibitor that is used to

Celltrion applies for FDA approval for Remsima SC

Celltrion applies for FDA approval for Remsima SC

Celltrion's Remsima Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoimmune disease treatment.Remsima SC (infliximab) is a self-injectable drug developed as a subcutaneous injection formulation.A C
(* comment hide *}